Spots Global Cancer Trial Database for trabectedin
Every month we try and update this database with for trabectedin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer | NCT00569673 | Fallopian Tube ... Ovarian Cancer Primary Periton... | filgrastim pegfilgrastim docetaxel trabectedin | 18 Years - 120 Years | GOG Foundation | |
| Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma | NCT00579501 | Liposarcoma,Myx... | Trabectedin Dexamethasone | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Leiomyosarcoma | NCT04535271 | Leiomyosarcoma | Trabectedin | 18 Years - | Sarcoma Oncology Research Center, LLC | |
| Geriatric Assessmen of Elderly "Unsuited" Patients Receiving Trabectedin in First Line Treatment For Advanced Soft Tissue Sarcomas (STS) | NCT03022448 | Advanced Soft-t... Metastatic Soft... | No Intervention | 60 Years - | GWT-TUD GmbH | |
| Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma | NCT04305548 | Mesenchymal Cho... | Trabectedin | 16 Years - | Italian Sarcoma Group | |
| A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT01846611 | Ovarian Neoplas... Peritoneal Neop... Fallopian Tube ... | Trabectedin DOXIL Dexamethasone DOXIL | 18 Years - | Janssen Research & Development, LLC | |
| Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma | NCT00005625 | Sarcoma | trabectedin | 12 Years - | Memorial Sloan Kettering Cancer Center | |
| Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer | NCT01735071 | Ovarian Epithel... | bevacizumab and... bevacizumab, tr... | 18 Years - | Mario Negri Institute for Pharmacological Research | |
| A Study to Investigate Efficacy & Safety of INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3) | NCT06263231 | Sarcoma,Soft Ti... | INT230-6 Eribulin Trabectedin Pazopanib | 18 Years - | Intensity Therapeutics, Inc. | |
| Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients | NCT04008238 | Soft Tissue Sar... Undifferentiate... Epithelioid Sar... Solitary Fibrou... Hemangioendothe... Desmoplastic Ro... Synovial Sarcom... | Trabectedin | 18 Years - | Institut Bergonié | |
| Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma | NCT02249702 | Leiomyosarcoma | gemcitabine + d... trabectedin | 18 Years - | Mario Negri Institute for Pharmacological Research | |
| A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma | NCT01343277 | Advanced Liposa... | Trabectedin Dacarbazine | 15 Years - | Janssen Research & Development, LLC | |
| Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS) | NCT02993705 | Carcinosarcoma,... Carcinosarcomas... | Trabectedin | 18 Years - 100 Years | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin Versus Doxorubicine in Patients With Leiomyosarcoma | NCT02997358 | Uterine or Soft... | Doxorubicin Trabectedin | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to Platinum | NCT05512676 | Ovarian Neoplas... Chemotherapeuti... Chemotherapy Ef... Chemotherapy-in... Chemotherapy-in... | 18 Years - 80 Years | Oslo University Hospital | ||
| Pharmacometabolomic of Trabectedin in Soft Tissue Patients | NCT04394728 | Sarcoma | Trabectedin | 18 Years - | Centro di Riferimento Oncologico - Aviano | |
| An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS) | NCT00796120 | Sarcoma | Trabectedin Doxorubicin Ifosfamide | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma | NCT00050440 | Endometrial Neo... Uterine Neoplas... Genital Neoplas... | Trabectedin Dexamethasone | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer | NCT01379989 | Ovarian Cancer | Carboplatin Pegylated Lipox... Trabectedin | 18 Years - | Mario Negri Institute for Pharmacological Research | |
| A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer | NCT00060944 | Liposarcoma Leiomyosarcoma | Yondelis Yondelis Dexamethasone Dexamethasone | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Leiomyosarcoma | NCT04535271 | Leiomyosarcoma | Trabectedin | 18 Years - | Sarcoma Oncology Research Center, LLC | |
| Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS) | NCT02398058 | Soft Tissue Sar... Bone Tumor | trabectedin olaparib | 18 Years - | Italian Sarcoma Group | |
| A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction | NCT01273493 | Neoplasm Metast... Hepatic Insuffi... | Trabectedin Dexamethasone | 18 Years - 70 Years | Janssen Research & Development, LLC | |
| A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma | NCT01692678 | Advanced or Met... | Trabectedin Dacarbazine | 15 Years - | Xian-Janssen Pharmaceutical Ltd. | |
| A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment | NCT00210665 | Sarcoma | Trabectedin | 15 Years - | Janssen Research & Development, LLC | |
| Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma | NCT00579501 | Liposarcoma,Myx... | Trabectedin Dexamethasone | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients | NCT02903004 | Ovarian Neoplas... | Trabectedin Pegylated Lipos... Topotecan Gemcitabine Weekly Paclitax... Carboplatin | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| Trabectedin for Recurrent Grade II/III Meningioma | NCT02234050 | Recurrent High ... | Trabectedin Local standard ... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor | NCT03023124 | Solitary Fibrou... | Trabectedin Adriamycin Dacarbazine | 18 Years - | Italian Sarcoma Group | |
| Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma | NCT03437070 | Leiomyosarcoma | Trabectedin Doxorubicin Olaratumab | 18 Years - | University of Miami | |
| Ecteinascidin 743 in Treating Adults With Advanced Solid Tumors | NCT00002904 | Unspecified Adu... | trabectedin | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Study in Patients With Advanced Soft Tissue Sarcoma (STS) After Failure of Anthracyclines and/or Ifosfamide | NCT01299506 | Soft Tissue Sar... | 18 Years - | PharmaMar | ||
| Patient Directed Intervention to Improve the Quality of Life for Patients With Soft Tissue Sarcoma | NCT02204111 | Soft Tissue Sar... | Intervention | 18 Years - | GWT-TUD GmbH | |
| Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma | NCT04979442 | Dedifferentiate... | RAIN-32 Trabectedin | 18 Years - | Rain Oncology Inc | |
| Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer | NCT03690739 | Recurrent Ovari... | Carboplatin Gemcitabine Bevacizumab PLD Paclitaxel PLD Trabectedin Cisplatin | 18 Years - | AGO Research GmbH | |
| Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus | NCT00379145 | Sarcoma | trabectedin | 18 Years - 120 Years | GOG Foundation | |
| An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer | NCT00580112 | Breast Neoplasm... | Dexamethasone Trabectedin | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients | NCT02275286 | Liposarcoma, My... Sarcoma, Soft T... Leiomyosarcoma Liposarcoma Pleomorphic Lip... | Trabectedin Radiotherapy | 18 Years - | Grupo Espanol de Investigacion en Sarcomas | |
| Ecteinascidin 743 in Treating Patients With Unresectable Advanced or Metastatic Soft Tissue Sarcoma | NCT00017030 | Sarcoma | trabectedin | 18 Years - | National Cancer Institute (NCI) | |
| A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma | NCT00102609 | Soft Tissue Sar... Sarcoma Neoplasms, Conn... Neoplasms by Hi... Neoplasms | Doxorubicin Trabectedin Dexamethasone | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma | NCT00003939 | Brain and Centr... Endometrial Can... Gastrointestina... Ovarian Cancer Sarcoma Small Intestine... | trabectedin | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors | NCT03127215 | Cancers With DN... | Olaparib Physician's cho... Trabectedin | 18 Years - 70 Years | National Center for Tumor Diseases, Heidelberg | |
| Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma | NCT03397186 | Myxoid Liposarc... Round Cell Lipo... Stage III Soft ... Stage IV Soft T... Metastatic Soft... Unresectable So... | Biopsy Laboratory Biom... Trabectedin | 18 Years - | Fred Hutchinson Cancer Center | |
| Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients | NCT02275286 | Liposarcoma, My... Sarcoma, Soft T... Leiomyosarcoma Liposarcoma Pleomorphic Lip... | Trabectedin Radiotherapy | 18 Years - | Grupo Espanol de Investigacion en Sarcomas | |
| Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer | NCT03690739 | Recurrent Ovari... | Carboplatin Gemcitabine Bevacizumab PLD Paclitaxel PLD Trabectedin Cisplatin | 18 Years - | AGO Research GmbH | |
| Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer | NCT03690739 | Recurrent Ovari... | Carboplatin Gemcitabine Bevacizumab PLD Paclitaxel PLD Trabectedin Cisplatin | 18 Years - | AGO Research GmbH | |
| INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer | NCT01379989 | Ovarian Cancer | Carboplatin Pegylated Lipox... Trabectedin | 18 Years - | Mario Negri Institute for Pharmacological Research | |
| Trabectedin Maintenance Post 1st-line in STS | NCT02929394 | Sarcoma, Soft T... | Trabectedin | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM) | NCT02194231 | Malignant Pleur... | Trabectedin | 18 Years - | Mario Negri Institute for Pharmacological Research | |
| Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients | NCT02825420 | Relapsed Ovaria... | trabectedin | 18 Years - | PharmaMar | |
| Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma Patients | NCT06050434 | Soft Tissue Sar... | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | ||
| Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma | NCT02247544 | Liposarcoma Leiomyosarcoma | Trabectedin | 18 Years - | Italian Sarcoma Group | |
| Pharmacometabolomic of Trabectedin in Soft Tissue Patients | NCT04394728 | Sarcoma | Trabectedin | 18 Years - | Centro di Riferimento Oncologico - Aviano | |
| A Study to Assess the Potential Effects of Ketoconazole on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies | NCT01267084 | Neoplasm Metast... | Trabectedin Ketoconazole Dexamethasone o... | 18 Years - | Janssen Research & Development, LLC | |
| Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery | NCT03074318 | Metastatic Leio... Metastatic Lipo... Unresectable Le... Unresectable Li... | Avelumab Trabectedin | 18 Years - | Fred Hutchinson Cancer Center | |
| Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin Versus Doxorubicine in Patients With Leiomyosarcoma | NCT02997358 | Uterine or Soft... | Doxorubicin Trabectedin | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Study in Patients With Advanced Soft Tissue Sarcoma (STS) After Failure of Anthracyclines and/or Ifosfamide | NCT01299506 | Soft Tissue Sar... | 18 Years - | PharmaMar | ||
| Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma | NCT00003939 | Brain and Centr... Endometrial Can... Gastrointestina... Ovarian Cancer Sarcoma Small Intestine... | trabectedin | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma | NCT02247544 | Liposarcoma Leiomyosarcoma | Trabectedin | 18 Years - | Italian Sarcoma Group | |
| Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin | NCT03773510 | Leiomyosarcoma Liposarcoma Synovial Sarcom... | Trabectedin dis... Trabectedin con... | 18 Years - | Italian Sarcoma Group | |
| Trabectedin for Recurrent Grade II/III Meningioma | NCT02234050 | Recurrent High ... | Trabectedin Local standard ... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer | NCT00060944 | Liposarcoma Leiomyosarcoma | Yondelis Yondelis Dexamethasone Dexamethasone | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer | NCT00050427 | Breast Neoplasm... Neoplasms Neoplasms by Si... Breast Diseases Skin Diseases | ET743 ET743 | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| A Phase 2 Study of Trabectedin (Yondelis) in Adult Male Participants With Advanced Prostate Cancer | NCT00072670 | Prostate Cancer | Trabectedin | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas | NCT03590210 | Metastatic Adul... | Trabectedin Nivolumab | 18 Years - | University Medicine Greifswald | |
| Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors | NCT03496519 | Solid Tumor, Ad... | Dose Escalation... Dose Expansion ... | 18 Years - 99 Years | University of Colorado, Denver | |
| Hyper-Thermia Enhanced Anti-tumor Efficacy of Trabectedin | NCT02359474 | Sarcoma | Trabectedin DNA double-stra... | 18 Years - | Ludwig-Maximilians - University of Munich | |
| Ecteinascidin 743 in Treating Adults With Advanced Solid Tumors | NCT00002904 | Unspecified Adu... | trabectedin | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram | NCT00786838 | Solid Tumor | Trabectedin Placebo | 18 Years - 65 Years | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Trabectedin First Line Therapy In Unfit Sarcoma Study | NCT02066675 | Metastatic and ... Standard Chemot... | Trabectedin | 18 Years - 80 Years | Italian Sarcoma Group | |
| Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma | NCT01189253 | Sarcoma | doxorubicin hyd... trabectedin laboratory biom... quality-of-life... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram | NCT00786838 | Solid Tumor | Trabectedin Placebo | 18 Years - 65 Years | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma | NCT03437070 | Leiomyosarcoma | Trabectedin Doxorubicin Olaratumab | 18 Years - | University of Miami | |
| Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic Sarcomas | NCT05131386 | Soft Tissue Sar... Bone Tumors Small Round-cel... | Trabectedin | 16 Years - 75 Years | Grupo Espanol de Investigacion en Sarcomas | |
| Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma | NCT03437070 | Leiomyosarcoma | Trabectedin Doxorubicin Olaratumab | 18 Years - | University of Miami | |
| Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue Sarcoma | NCT01303094 | Soft Tissue Sar... Uterine Sarcoma | Trabectedin Drug: holiday | 18 Years - | Centre Oscar Lambret | |
| Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic Sarcomas | NCT05131386 | Soft Tissue Sar... Bone Tumors Small Round-cel... | Trabectedin | 16 Years - 75 Years | Grupo Espanol de Investigacion en Sarcomas | |
| ET 743 (Yondelis) in Men With Advanced Prostate Cancer | NCT00147212 | Prostate Cancer | ET 743 | 18 Years - | Massachusetts General Hospital | |
| Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors | NCT00070109 | Previously Trea... Recurrent Child... Recurrent Child... Recurrent Ewing... Peripheral Prim... | trabectedin pharmacological... | 12 Months - 50 Years | Children's Oncology Group | |
| Patient Directed Intervention to Improve the Quality of Life for Patients With Soft Tissue Sarcoma | NCT02204111 | Soft Tissue Sar... | Intervention | 18 Years - | GWT-TUD GmbH |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
